Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical distributors selling counterfeit versions of its antiretroviral therapies to three pharmacies in the United States. The move comes after the company became aware of the situation in 2020. The products primarily affected include the complete anti-HIV-1 regimen Symtuza (darunavir + cobicistat + emtricitabine + tenofovir alafenamide), as well as Edurant (rilpivirine), Intelence (etravirine), Prezcobix (darunavir + cobicistat), and Prezista (darunavir).
Supporting FDA Investigation and Securing Distribution
In addition to the legal action, Janssen has been actively supporting an investigation by the local Food and Drug Administration (FDA). The company has taken significant steps to secure its distribution system, ensuring the authenticity and safety of its products. Janssen has also adopted special packaging and printing techniques to make it more difficult for counterfeiters to replicate their products.
Guidance for Stakeholders
To further combat the issue, Janssen has provided guidance to stakeholders on how to identify authentic products. This proactive approach aims to educate pharmacies and healthcare providers on the signs of counterfeit drugs, thereby protecting patients from the risks associated with substandard or fake medications.-Fineline Info & Tech
